An experimental drug to treat multiple sclerosis (MS) decreased the rate of disease progression as well as led to significant improvement in patients with MS. French biotechnology firm MedDay announced the encouraging results of the drug on April 24.
"This is the first time that a drug has been able to decrease the rate of disease progression in addition to improving a significant proportion of patients with progressive MS," said MedDay CEO Frederic Sedel in a statement.
Multiple Sclerosis
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or insulating layer of the nerve fibers and typically has remissions and relapses
Advertisement
The experimental MD1003 drug underwent Phase III clinical trial, the last stage before filing for authorization to market the drug in the treatment of primary and secondary progressive multiple sclerosis.
The results of the study, presented at the annual meeting of the American Academy of Neurology, were encouraging, said Professor Ayman Tourbah, the study's principal investigator.
![Experimental Antibody Drug Protects Nerves from Multiple Sclerosis]( "Experimental Antibody Drug Protects Nerves from Multiple Sclerosis")
An experimental antibody drug aimed at protecting nerves from multiple sclerosis offers hope for a new way to combat the neurological disease.
"The rapid rate of recruitment into this multi-centre study illustrates the serious need for a well-tolerated drug by patients with primary and secondary progressive multiple sclerosis," he added in the company's statement.
"The significant proportion of patients showing improvement at twelve months, coupled with the decrease in risk of disease progression demonstrated here, makes MD1003 a potentially important new therapy for patients and clinicians in the field of MS."
The application process to license the drug will begin when all the test results are in, expected by the end of the year.
Source: Medindia
Experimental Antibody Drug Protects Nerves from Multiple Sclerosis
An experimental antibody drug aimed at protecting nerves from multiple sclerosis offers hope for a new way to combat the neurological disease.
Advertisement
"The rapid rate of recruitment into this multi-centre study illustrates the serious need for a well-tolerated drug by patients with primary and secondary progressive multiple sclerosis," he added in the company's statement.
"The significant proportion of patients showing improvement at twelve months, coupled with the decrease in risk of disease progression demonstrated here, makes MD1003 a potentially important new therapy for patients and clinicians in the field of MS."
The application process to license the drug will begin when all the test results are in, expected by the end of the year.
Source: Medindia
An Over-The-Counter Foot Cream Shows Possibilities of Cure for Multiple Sclerosis
Drug components found in a foot cream that treats eczema could catalyze the body's own stem cells to replace the cells lost in multiple sclerosis.
Advertisement
 Activity Tracking Device Boosts Confidence in Patients With Multiple SclerosisSuch devices can measure number of steps, distance walked, and sleep quality of a person with MS continuously. This could potentially supplement office visits. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
Women using hormonal contraception, along with their healthcare providers, should explore alternative pain relief options instead of NSAIDs.
The recently created assay identifies antipsychotic drugs present in sweat.
